Cellectis
Data Breaches, Cyber Attacks and Security Report

https://cellectis.com  ᛫  Biotech & Pharmaceuticals
Last updated November 12, 2019

About Cellectis

Company Overview

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.

Valuation

Employees

CEO

André Choulika

Location

Data Breaches and Security News

Cellectis Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Cellectis is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Cellectis

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Cellectis's security performance with other companies